JNCCN 360

Advertisement

Advertisement

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: Reducing the Frequency of Nivolumab Dosing

Nicholas Vogelzang, MD, on Urothelial Cancer: Lenvatinib Plus Pembrolizumab

Sarah A. Holstein, MD, PhD, on Multiple Myeloma: New Induction Therapies

Recent

SOHO 2019: Update on the Future of Induction Therapy in Multiple Myeloma

WCLC 2019: 5-Year Overall Survival With Nivolumab From CheckMate Trials

Assessing Risk of Immunomodulatory Drug–Related Blood Clots in Patients With Multiple Myeloma

Venetoclax Plus Obinutuzumab in Patients With Untreated CLL

Published

Medical Literature

Nivolumab for Advanced Melanoma: 5-Year Survival

Two Phase III Trials Evaluating Daratumumab-Based Therapies for Multiple Myeloma

Dosing Schedule for Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma

Niraparib Plus Pembrolizumab in Recurrent Platinum-Resistant Ovarian Carcinoma

Ongoing

Combined CAR-T Targeting Yields High Response Rate in Myeloma

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

Immunotherapy for cSCC: How, Why, and When (login required)

Cases From the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients With Genitourinary Cancers

Available

Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials

ClinicalTrials.gov Immunotherapy

Center for Immunotherapy Clinical Research Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

NCCN Resources

Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.